Fundraising FoxThynk Capital
Venture capitalPre-Seed–Series A · 1 people tracked
Find your way into Thynk Capital
49 people in our graph share verified history with the Thynk Capital team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Thynk Capital focuses on early-stage therapeutics, healthcare, and technology companies, supplying growth capital and value-added resources to optimize performance and increase enterprise value while targeting above-market returns for limited partners. The firm works closely with portfolio companies to improve operational efficiency, strengthen management teams, and build strategic growth roadmaps. It is expanding into early-stage pharma and biotech focused on extending healthspan and addressing major diseases of aging such as Alzheimer's, dementia, kidney disease, cancer, cardiovascular disease, diabetes, frailty, and rare disease. The firm also emphasizes accelerating cutting-edge technology and building a platform of innovation.
Source: firm website, verified Aug 3, 2026.
What founders say
No founder feedback on Thynk Capital yet.
Team · 1 people
from the firm's website
What they invest in
from 15 of 17 portfolio companiesBiotech ×10Healthtech ×7Medical Devices ×7Digital Health ×3Enterprise Software ×2Hardware ×2Longevity ×2SaaS ×2
HQs:United States×12
Investments · 17 tracked
founders shown can be your intro pathBy year:2020 · 12019 · 12018 · 12017 · 22015 · 16 dated
X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia.
BiotechBoston, US
Mary DiBiase(Executive Officer)inChristophe Arbet-Engels(Executive Officer)inDavid Kirske(Executive Officer)inJohn Volpone(Executive Officer)inMark Baldry(Executive Officer)Adam Craig(Executive Officer, Director)in
PartnerJim Plante· solo GP
Co-investorsBain Capital Life SciencesLumira VenturesNew Enterprise Associates (NEA)Partners ResoluteAdvent Life SciencesOmega Funds+1 more
Encinitas, US
Edward White(Executive Officer)Charles H. Silver(Executive Officer, Director)David L.R. Stein(Executive Officer)
BoardLorenzo Thione(Director)Robert Bingham(Director)Edgar F. Berner(Director)
PartnerJim Plante· solo GP
Curtana Pharmaceuticals develops small molecule drugs targeting cancer stem cells in brain tumors, specifically gliomas and related CNS malignancies.
BiotechDigital HealthMedical DevicesAustin, US
Gregory Stein(Chief Executive Officer, Co-Founder, Chairman)
PartnerJim Plante· solo GP
E-Band Communications manufactures ultra-low latency wireless radio systems operating in the 70/80 GHz and 71-86 GHz frequency bands for financial networks and mobile backhaul.
Defense TechEnterprise SoftwareHardware
Jamal Hamdani(CEO, Axxcss Wireless Solutions, Inc. and subsidiaries)
PartnerJim Plante· solo GP
Elevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation.
BiotechHealthtechLongevityMenlo Park, US
Mark Allen(Executive Officer, Director)inCasey J McGlynn(Executive Officer)Sebastian Giwa(Executive Officer, Director)inLuis Alvarez(Executive Officer)Daniel Marshak(Director)
BoardSuzanne Fletcher(Director)
PartnerJim Plante· solo GP
Co-investorsBold Capital PartnersFor Good VenturesLauder PartnersPrime Movers LabWTI
Fisker is an electric vehicle maker whose Ocean model is the subject of NHTSA recall repair and reimbursement processing.
CleantechHardwareMobility & TransportationManhattan Beach, US
Geeta Gupta(Executive Officer, Director, Promoter)inHenrik Fisker(Executive Officer, Director, Promoter)William R. McDermott(Director)Mark Hickson(Director)Roderick K. Randall(Director)
BoardNadine Watt(Director)
PartnerJim Plante· solo GP
Co-investorsCapital Q® Ventures Inc.
Geospan develops geospatial information and aerial imagery analytics solutions for the insurance and property management industries.
Cloud ComputingConstruction TechData & InfrastructureInsurTechPropTechSaaSMinneapolis, US
Ted Lachinski(President)in
PartnerJim Plante· solo GP
PartnerJim Plante· solo GP
IVIVA Medical develops fully implantable bioartificial kidneys as a potential cure for patients with chronic kidney disease, diabetes, and kidney failure.
BiotechHealthtechMedical DevicesBeverly, US
Harald C Ott(Director)Brock Reeve(Executive Officer)
PartnerJim Plante· solo GP
Co-investorsBold Capital PartnersPrime Movers LabWI Harper Group
Kito Technology Medical develops microMend, a wound closure device that uses miniature staples and cantilever springs to close cuts and lacerations without needles or sutures.
ConsumerHealthtechMedical DevicesMercer Island, US
Ronald Berenson(Executive Officer, Director, Promoter)
PartnerJim Plante· solo GP
Co-investorsElevate CapitalKeiretsu ForumPallasite Ventures
Klotho Therapeutics is a biotech company developing protein-based therapeutics that mimic the natural human Klotho protein to address age-related diseases including cognitive decline, kidney disease, diabetes, and cancer.
BiotechHealthtechLongevity
PartnerJim Plante· solo GP
Lubricin (PRG4) is a glycoprotein found naturally in the human body that lubricates and protects tissue surfaces from friction and wear.
BiotechHealthtechMedical Devices
PartnerJim Plante· solo GP
Co-investorsTarnagulla Ventures
Repair Biotechnologies develops the Cholesterol Degrading Platform, a therapeutic approach for treating conditions caused by localized accumulations of excess cholesterol.
BiotechHealthtechMedical DevicesSyracuse, US
Guilherme Cherman Perdigao de Oliveira(Executive Officer, Director)Reason("CEO's full legal name is ""Reason""")Anthony Matthew Chow(Director)
BoardKelsey Moody(Director)
PartnerJim Plante· solo GP
Co-investorsquadraScope Venture Fund
SmartDrive Systems provides video-based fleet safety and analytics solutions for commercial transportation companies, including trucking fleets and transit systems, to prevent collisions and improve driver performance.
Enterprise SoftwareIoTLogistics & Supply ChainSaaS
PartnerJim Plante· solo GP
Co-investorsNew Enterprise Associates (NEA)NewView CapitalOak Investment PartnersSixth Street
Theragene Pharmaceuticals develops immunotherapy and gene therapy treatments for cancer and cardiovascular diseases using AAV technology.
BiotechDigital HealthMedical DevicesSan Diego, US
Jon Berglin(Executive Officer, Director)
BoardSteven Davis(Director)Daniel Coury(Director)Chaojie Zhang(Director)
PartnerJim Plante· solo GP
Viscient Biosciences develops drugs by studying human 3D tissue models combined with multi-omics analysis to understand disease mechanisms.
BiotechDeep TechDigital HealthSan Diego, US
PartnerJim Plante· solo GP
Winsantor is a clinical-stage biotechnology company developing treatments for peripheral neuropathies, including diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy.
BiotechHealthtechMedical DevicesSan Diego, US
Stan Kim(Executive Officer, Director)inNigel Calcutt(Director)
PartnerJim Plante· solo GP
Exits · 1
1 IPOsX4 PharmaNASDAQ: XFOR
Portfolio news
latest coverage across their companiesFrequently asked questions
- How many investments has Thynk Capital made?
- Thynk Capital has 17 tracked investments, 1 of which have exited.
- What stage does Thynk Capital invest at?
- Thynk Capital invests at the Pre-Seed, Seed, Series A stages.
- What sectors does Thynk Capital focus on?
- Thynk Capital focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Who does Thynk Capital co-invest with?
- Thynk Capital most often shares deals with Bold Capital Partners, New Enterprise Associates (NEA), Lumira Ventures, among 16 tracked co-investors.
Similar investors
Future Positive Capital is a venture firm backing entrepreneurs building companies that address large-scale global challenges across health, sustainability and technology.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Medical Excellence Capital (MEC) is a venture firm focused on precision health and life sciences, pairing investment professionals and operators with a proprietary national medical network platform.
Snatched Ventures is a San Francisco-based early-stage venture capital firm backing DeepTech startups focused on sustainable innovation and operational transformation. It is led by a two-GP team combining corporate development and institutional investment management experience.
Crista Galli Ventures is a family office founded and run by physician scientists that invests in health and life-science innovation, backing exceptional founders and evidence-driven breakthroughs.